- Brand names:
- Pharmaceutical Company:
- Condition/Indication:
- Meeting Date: November 2016
- Public Summary Document (PSD) November 2016 PBAC Meeting - PDF
- Public Summary Document (PSD) November 2016 PBAC Meeting - Word
Pembrolizumab (nsclc) – November 2016
Pembrolizumab (NSCLC): Powder for injection 50 mg; Keytruda®
Last updated
23 March 2017